tiprankstipranks
Advertisement
Advertisement

JAZZ Stock Latest News

Jazz Pharmaceuticals price target raised to $225 from $224 at Barclays
The FlyJazz Pharmaceuticals price target raised to $225 from $224 at Barclays
3d ago
JAZZ
Nike downgraded, IBM initiated: Wall Street’s top analyst calls
PremiumThe Fly
Nike downgraded, IBM initiated: Wall Street’s top analyst calls
13d ago
BDX
CCC
Jazz Pharmaceuticals resumed with an Outperform at Raymond James
PremiumThe Fly
Jazz Pharmaceuticals resumed with an Outperform at Raymond James
13d ago
JAZZ
Jazz Pharmaceuticals price target raised to $232 from $219 at Piper Sandler
PremiumThe Fly
Jazz Pharmaceuticals price target raised to $232 from $219 at Piper Sandler
1M ago
JAZZ
Jazz Pharmaceuticals to present clinical, preclinical data at AACR 2026
PremiumThe Fly
Jazz Pharmaceuticals to present clinical, preclinical data at AACR 2026
1M ago
JAZZ
Zymework’ partner Jazz to present on Ziihera at 2026 AACR Annual Meeting
PremiumThe FlyZymework’ partner Jazz to present on Ziihera at 2026 AACR Annual Meeting
1M ago
JAZZ
ZYME
3 Best Value Stocks with Over 10% Upside in 2026, According to Analysts 
Premium
Market News
3 Best Value Stocks with Over 10% Upside in 2026, According to Analysts 
1M ago
PCG
RCL
Jazz Pharmaceuticals price target raised to $226 from $225 at Deutsche Bank
Premium
The Fly
Jazz Pharmaceuticals price target raised to $226 from $225 at Deutsche Bank
2M ago
JAZZ
Jazz Pharmaceuticals Balances Record Gains With Slower 2026
PremiumCompany Announcements
Jazz Pharmaceuticals Balances Record Gains With Slower 2026
2M ago
JAZZ
Zymeworks, Royalty Pharma enter $250M royalty-backed note financing
PremiumThe Fly
Zymeworks, Royalty Pharma enter $250M royalty-backed note financing
2M ago
ONC
JAZZ
Jazz Pharmaceuticals Advances ONC206 Trial in Rare Tumors, Offering a New Pipeline Catalyst for JAZZ
PremiumCompany Announcements
Jazz Pharmaceuticals Advances ONC206 Trial in Rare Tumors, Offering a New Pipeline Catalyst for JAZZ
2M ago
JAZZ
Jazz Pharmaceuticals initiated with an Overweight at Barclays
PremiumThe Fly
Jazz Pharmaceuticals initiated with an Overweight at Barclays
2M ago
JAZZ
Jazz Pharmaceuticals price target raised to $226 from $225 at Morgan Stanley
PremiumThe FlyJazz Pharmaceuticals price target raised to $226 from $225 at Morgan Stanley
2M ago
JAZZ
Jazz Pharmaceuticals price target raised to $255 from $210 at Deutsche Bank
Premium
The Fly
Jazz Pharmaceuticals price target raised to $255 from $210 at Deutsche Bank
2M ago
JAZZ
Jazz Pharmaceuticals price target raised to $275 from $263 at BofA
Premium
The Fly
Jazz Pharmaceuticals price target raised to $275 from $263 at BofA
2M ago
JAZZ
Jazz Pharmaceuticals price target raised to $250 from $235 at Wells Fargo
PremiumThe Fly
Jazz Pharmaceuticals price target raised to $250 from $235 at Wells Fargo
2M ago
JAZZ
Jazz Pharmaceuticals: Underappreciated Growth Story with Durable Sleep Franchise and Pipeline-Driven Upside
PremiumRatings
Jazz Pharmaceuticals: Underappreciated Growth Story with Durable Sleep Franchise and Pipeline-Driven Upside
2M ago
JAZZ
Jazz Pharmaceuticals reports Q4 adjusted EPS $6.64 vs. $6.51 last year
PremiumThe Fly
Jazz Pharmaceuticals reports Q4 adjusted EPS $6.64 vs. $6.51 last year
2M ago
JAZZ
Jazz Pharmaceuticals sees FY26 revenue $4.25B-$4.5B, consensus $4.5B
PremiumThe Fly
Jazz Pharmaceuticals sees FY26 revenue $4.25B-$4.5B, consensus $4.5B
2M ago
JAZZ
JAZZ Earnings this Week: How Will it Perform?
PremiumPre-EarningsJAZZ Earnings this Week: How Will it Perform?
2M ago
JAZZ
ALX Oncology announces new data from Phase 1b/2 trial of evorpacept, Ziihera
Premium
The Fly
ALX Oncology announces new data from Phase 1b/2 trial of evorpacept, Ziihera
3M ago
ALXO
JAZZ
Jazz Pharmaceuticals price target raised to $220 from $205 at TD Cowen
Premium
The Fly
Jazz Pharmaceuticals price target raised to $220 from $205 at TD Cowen
3M ago
JAZZ

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >